383150-41-2
中文名稱
JTE-013
英文名稱
JTE-013
CAS
383150-41-2
分子式
C17H19Cl2N7O
分子量
408.29
MOL 文件
383150-41-2.mol
更新日期
2025/01/15 10:03:13
383150-41-2 結(jié)構(gòu)式
基本信息
中文別名
化合物JTE-013N-(2,6-二氯-4-吡啶基)-2-[1,3-二甲基-4-異丙基-1H-吡唑并[3,4-B]吡啶-6-基]肼基甲酰胺
英文別名
CS-2553JTE-013
JTE 013
JTE013
1-(2,6-dichloro-4-pyridyl)-3-[(4-isopropyl-1,3-dimethyl-pyrazolo[3,4-b]pyridin-6-yl)amino]urea
1-(2,6-dichloropyridin-4-yl)-3-[(1,3-dimethyl-4-propan-2-ylpyrazolo[3,4-b]pyridin-6-yl)amino]urea
1-[1,3-Dimethyl-4-(2-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-(3,5-dichloro-4-pyridinyl)-semicarbazide
1-[1,3-Dimethyl-4-(2-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-(2,6-dichloro-4-pyridinyl)-semicarbazide
N-(2,6-Dichloro-4-pyridinyl)-2-[1,3-dimethyl-4-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]hydrazinecarboxamide
Hydrazinecarboxamide, N-(2,6-dichloro-4-pyridinyl)-2-[1,3-dimethyl-4-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-
物理化學(xué)性質(zhì)
密度1.50±0.1 g/cm3(Predicted)
儲存條件2-8°C
溶解度二甲基亞砜：≥20mg/mL
酸度系數(shù)(pKa)9.32±0.43(Predicted)
形態(tài)粉末
顏色白色至灰白色
常見問題列表
生物活性
JTE-013 是一種有效且選擇性的 S1P2 (鞘氨醇1-磷酸2) 拮抗劑。JTE-013 抑制放射性標(biāo)記的 S1P 與人和大鼠 S1P2 的特異性結(jié)合，IC50 分別為 17 nM 和 22 nM。靶點(diǎn)
IC50: 17 nM (S1P 2 for human) and 22 nM (S1P 2 for rat)
體外研究
JTE-013 (50-200 μM; 1-3 days) reduced cell viability.
JTE-013 (10-1000 nM; 30 mins) reverses S1P-induced Akt inhibition and inhibits S1P-induced ERK activation.
JTE-013 displays 4.2% inhibition of S1P
3
and does not antagonize S1P
1
at concentrations up to 10 μM.
Cell Viability Assay
| Cell Line: | SK-N-AS cells |
| Concentration: | 50, 100, 150, 200 μM |
| Incubation Time: | 1-3 days |
| Result: | Reduced cell viability. |
Western Blot Analysis
| Cell Line: | SK-N-AS cells |
| Concentration: | 10, 100, 1000 nM |
| Incubation Time: | 30 mins |
| Result: | Reversed S1P-induced Akt inhibition and inhibited S1P-induced ERK activation. |
體內(nèi)研究
JTE-013 (gavage; 30 mg/kg daily for 14 consecutive days) reduces tumor size and tumor weight.
| Animal Model: | Six-week-old female athymic NCr-nu/nu nude mice |
| Dosage: | 30 mg/kg |
| Administration: | Gavage; daily for 14 consecutive days |
| Result: | Reduced tumor size and tumor weight. |